OR WAIT null SECS
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
New York-Pfizer Inc. and Eyetech Pharmaceuticals Inc. will jointly develop and commercialize Eyetech's pegaptanib sodium (Macugen) as a potential treatment for age-related macular degeneration (AMD) and diabetic macular edema (DME).